A new cell therapy data package strengthened the feasibility case for Parkinson’s replacement strategies as a stem cell-derived dopamine progenitor program advanced to first-in-human clinical results. The STEM-PD Phase 1/2 open-label trial reported initial findings on safety and feasibility from eight participants, with publication in Nature Medicine. On the preclinical translational pipeline, Baylor College of Medicine and collaborators reported a genetically engineered rat approach for estrogen receptor-positive (ER+) breast cancer modeling using CRISPR-Cas9-based somatic genome editing. The platform aims to create more authentic tumor biology for testing therapeutics and biomarker strategies. Separately, researchers described progress toward mapping stem cell fate in the pancreas—clarifying how stem cells commit to alpha- vs beta-cell lineages to enable improved stem cell-derived islet generation for diabetes. Together, the updates highlight continued momentum across cell replacement and disease modeling, moving from mechanism and fate decisions to early clinical feasibility—an essential bridge for scaling therapeutic candidacy.